Page 2474 - Williams Hematology ( PDFDrive )

2445
2444 Index Index 2445

venous thromboembolism risk and, High-density lipoprotein (HDL), 2283 for polycythemia vera, 1300
2221–2222, 2225–2226, 2225t, activated protein C and, 1956 for sickle cell disease, 774t, 775
2226t, 2268, 2268t atherosclerosis and, 2287–2288 Histone deacetylases (HDACs), 239–240,
Hereditary xerocytosis, 682t, 683 disseminated intravascular coagulation 239t, 240f, 1838
Hermansky-Pudlak syndrome (HPS) and, 2203 Histone modification, 167–168, 167f, 234t
clinical features, 1229, 2053 familial deficiency, 684 Histoplasma infection, 384
differential diagnosis, 1020 High endothelial venules (HEVs), 68, 93 History taking, 3–7, 4t
etiology and pathogenesis, 1229, 1818, High-mobility group protein-1/2 (HMG1/2), HIT. See Heparin-induced thrombocytopenia
1843, 1871, 2052–2053, 2053f 1167 (HIT)
laboratory features, 2053–2054 High-molecular-weight kininogen (HK), HIV. See under Human immunodeficiency
therapy, course, and prognosis, 2054 1916t, 1929 virus
Herpes simplex virus (HSV) infections High-throughput DNA sequencing HIVEP2, 1787
encephalitis, 304, 1230 technologies. See Next-generation HJV (hemojuvelin), 566, 621, 621t, 642
after hematopoietic cell transplantation, sequencing HJV (hemojuvelin) mutations, 642
370 Hill plot, 761 HK. See Hexokinase (HK)
in immunocompromised host, 384 Hip fracture repair, 2370–2371, 2370t HK (high-molecular-weight kininogen),
Herpes simplex virus thymidine kinase Hirudin, 1919 1916t, 1929
(HSV-TK), 440 Hispanic Americans, sickle cell disease and, HK1, 694
Herpesviruses. See under Human herpes 763 HLA. See under Human leukocyte antigen
virus (HHV) HIST1H1B-E mutations, 235t (HLA)
Herpes zoster Histamine, 286t, 289, 1448, 1979t HLH. See Hemophagocytic
idiopathic CD4+ T lymphocytopenia and, Histidine catabolism, 586t lymphohistiocytosis (HLH)
1206 Histiocytes, 1089, 1101, 1102t, 1446. See also HMG1/2 (high-mobility group protein-1/2),
prophylaxis, 1746 Macrophages 1167
15-HETE, 952 Histiocytic lymphoma, 1569 HMGA2, 1321
HETE1, 1877 Histiocytosis(es) HNAs. See Human neutrophil antigens
Heterogenous nucleation, 763 classification, 1090–1091, 1090t, 1101, (HNAs)
Heterophile antibody test, 1261 1102t HO (heme oxygenase), 499
HEVs (high endothelial venules), 68, 93 definition, 1089 Hodgkin cells, 1605, 1606
Hexagonal phase assay, 2243 effects, 1092 Hodgkin lymphoma, 1603–1618
Hexokinase (HK), 497, 692t, 694 Erdheim-Chester disease, 1101, 1102t, anatomic distribution of disease, 1609
Hexokinase (HK) deficiency, 694, 700t, 704, 1110–1111 classical, 1497t, 1599–1600, 1599f, 1604t
2061 hemophagocytic lymphohistiocytosis. lymphocyte-depletion subtype, 1609
L-Hexonate dehydrogenase, 697 See Hemophagocytic lymphocyte-rich subtype, 1609
Hexose monophosphate shunt, 693f, 694, lymphohistiocytosis (HLH) mixed cellularity subtype, 1600, 1600f,
694f, 932 juvenile xanthogranuloma, 1101, 1102t, 1609
HFE, 621, 621t, 623 1111–1112 nodular sclerosis subtype, 1600, 1600f,
HFE Langerhans cell. See Langerhans cell 1609
epidemiology, 640 histiocytosis classification, 1493, 1497t, 1604t
hemochromatosis and, 642 malignant, 1101, 1102t, 1109–1110 clinical features, 1607–1609
porphyria cutanea tarda and, 889, 907 sinus histiocytosis with massive course and prognosis, 1613t, 1616–1617
2-HG (2-hydroxyglutarate), 198 lymphadenopathy (Rosai-Dorfman definition and history, 1603–1604
HHT (hereditary hemorrhagic disease), 1112–1113 differential diagnosis, 1610
telangiectasia), 629, 1986, 1987, Histiocytosis X. See Langerhans cell epidemiology, 1571f, 1604–1605, 1604f,
2108–2109, 2109f, 2172 histiocytosis 1605f
HHV. See under Human herpes virus (HHV) Histone acetylases (HATs), 240 etiology and pathogenesis
HIES (hyperimmunoglobulin E syndrome), Histone acetyltransferase (HAT) enzymes, genetic basis, 1605
1020t, 1026–1027, 1182, 1225 167f, 168 infectious, 1605
HIF. See Hypoxia-inducible transcription Histone deacetylase (HDAC) inhibitors, microenvironment, 1607
factor (HIF) 336–337. See also specific drugs Reed-Sternberg cell, 1605–1606, 1605f,
High-affinity folate receptors, 588 for acute myelogenous leukemia, 1607f
High-altitude polycythemia 1403 HIV-associated
clinical features, 881 mechanism of action, 240 antiretroviral therapy and chemotherapy
epidemiology, 873 for mycosis fungoides, 1686–1687 for, 1248
etiology and pathogenesis, 874–875, 874f for myelodysplastic syndromes, 1361 characteristics, 1247, 1248t
treatment, 884 for myeloma, 1754 chemotherapy for, 1247–1248

Kaushansky_index_p2393-2506.indd 2445 9/21/15 3:22 PM